EMEA-002979-PIP03-21 - paediatric investigation plan

pamrevlumab

Key facts

• Active substance:
  pamrevlumab
• Therapeutic area:
  Oncology
• Decision number:
  P/0508/2021
• PIP number:
  EMEA-002979-PIP03-21
• Pharmaceutical form(s):
  All pharmaceutical forms
• Condition(s) / indication(s):
  Treatment of pancreatic cancer
• Route(s) of administration:
  All routes of administration
• Decision type:
  W: decision granting a waiver in all age groups for all conditions or indications
• Decision date:
  03/12/2021
• Compliance check done:
  No

Decision

P/0508/2021 - EMA decision of of 3 December 2021 on the granting of a product specific waiver for pamrevlumab, (EMEA-002979-PIP03-21)

Adopted Reference Number: EMA/624231/2021